COMP <GO>
QGEN vs UNH // 10Y YIELD & FRED MACRO BETA
Qiagen N.V. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: QGEN 6
— UNH 8
▲ 10Y YIELD & FRED MACRO BETA LEADER: QGEN
LAST: $50.35 (+0.26%) • MKT CAP: $10.35B
macro-sensitivity
0.95
LAST: $400.44 (-1.60%) • MKT CAP: $365.29B
macro-sensitivity
0.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QGEN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QGEN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.20% | 88.57% | -26.37 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.00% | 11.47% | -3.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | 16.5x | +1.12 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 6.47% | -2.10 | UNH | /fcf-yield <GO> |
| Operating Margin | 22.30% | 4.82% | +17.48 | QGEN | /operating-margins <GO> |
| Net Profit Margin | 20.30% | 3.14% | +17.16 | QGEN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 6.46% | -0.76 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.52% | 2.32% | -1.80 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 3.12 | +0.42 | QGEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | QGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.11% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 71.0 | 57.4 | +13.60 | QGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.95 | 0.33 | +0.62 | QGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.7x | 17.7x | +4.96 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.35B | $365.29B | -$354.95B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QGEN REV | UNH REV | QGEN GROSS % | UNH GROSS % | QGEN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.09B | $447.57B | 62.2% | 88.7% | $453.3M | $16.07B |
| FY 2024 | $1.98B | $400.28B | 48.9% | 88.3% | $506.4M | $20.70B |
| FY 2023 | $1.97B | $371.62B | — | 89.6% | $371.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QGEN // BETA 0.95
UNH // BETA 0.33